Breast, A011801
CompassHer2 Residual Disease (RD): Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Breast, A191901
Optimizing endocrine therapy through motivational interviewing and text interventions
Breast, ASCENT-05/ GS-US-595-6184/ AFT-65
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Breast, Cambria 1 D8531C00002
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Breast, Cambria-2 D8535C00001
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy).
Breast, CELC-G-301
Viktoria-1 Gedatolisib in Combination with Palbociclib and Fulvestrant Compared to SOC in Previously Treated Pts with HR-Positive, HER2 Negative Advanced Breast Cancer
Breast, NRG-BR007
DEBRA-De-escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18
Breast, NRG-CC011
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.
Breast, OptimICE-pCR: A012103
This phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab.
Breast, Pfizer-C4891001
VERITAC-2- Open-Label Trial of ARV-471 (PF-07850327) vs. Fulvestrant in PTS W/ ER-Positive, HER2-Negative Advanced Breast Cancer w/ Disease Progression After Prior Endocrine Rx For Advanced Disease
Breast, TOL2506A
Ovarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA)
